Effects of In Vivo Administration of Interleukin-2 (IL-2) and IL-4, Alone and in Combination, on Ex Vivo Human Basophil Histamine Release

By Martha V. White, Yasushi Igarashi, Brian E. Emery, Michael T. Lotze, and Michael A. Kaliner

Human basophils possess receptors for interleukin-2 (IL-2) and IL-4. The effect of 3 days of intravenous administration of IL-2 and/or IL-4 on basophil histamine release was examined in three groups of patients receiving IL-2, IL-4, or the combination of agents as part of a protocol to treat malignant melanoma or renal cell carcinoma. Because all patients received ranitidine for control of side effects, a control group of patients receiving ranitidine for Zollinger-Ellison syndrome was also studied. IL-4 significantly inhibited IgE-mediated histamine release, while there was a trend for enhancement of IgE-mediated histamine release by IL-2. Administration of the combination of IL-2 and IL-4 did not alter IgE-mediated basophil histamine release. Both IL-2 and IL-4, alone and in combination, enhanced basophil histamine release induced by histamine releasing factors in human nasal washings. The effect of IL-2 alone was significantly greater than that of IL-4 alone or the combination of IL-2 plus IL-4. Taken together, the data suggest that when coadministered, IL-4 may inhibit the effects of IL-2 on basophils. Neither cytokine exerted any effect on basophil histamine release induced by the calcium ionophore A23187, nor did ranitidine cause any effects on histamine release induced by any of the stimulants. Thus, human basophil reactivity can be affected by IL-2 and by IL-4. The role that these two cytokines play in basophil function in vivo is likely to be complex.

HUMAN BASOPHILS are circulating effector cells capable of migrating into tissues and playing a role in allergic and other inflammatory reactions. Basophils are known to possess high-affinity IgE receptors capable of mediating antigen-induced degranulation and in mast cells, cytokine transcription as well. Recently, a single class of high-affinity interleukin-3 (IL-3) and IL-4 receptors, as well as a single class of low-affinity IL-2 receptors, have been shown on human basophils enriched from the blood of patients with chronic granulocytic leukemia. IL-3 has been shown to regulate basophil growth and differentiation, and can by itself stimulate basophil histamine release as well as enhance antigen-induced basophil histamine release. The exact role of the basophil IL-4 receptor is uncertain. However, IL-4 can enhance the basophil growth promoting effects of IL-3. In addition, IL-4 promotes the differentiation of B lymphocytes from IgM-bearing cells to IgE-secreting plasma cells, and is necessary for sustained secretion of IgE, which might then be available to bind the high-affinity IgE receptors on basophils. IL-4 has been shown to induce low levels of histamine release in vitro from basophils of patients with acquired immunodeficiency syndrome (AIDS), but has no degranulating effect on the basophils of either normal or atopic individuals. Little data exist on the function of the basophil IL-2 receptor. IL-2 alone does not cause basophil histamine release, but has been reported to enhance IgE-, A23187-, and FMLP-induced basophil histamine release at high doses, and to inhibit release at low doses.

No studies of the effects of in vivo administration of either IL-4 or IL-2 on basophil reactivity have been published. At the National Institutes of Health (NIH), the effects of IL-2 and IL-4, alone and in combination, on renal cell carcinoma or malignant melanoma were studied. The major adverse effects experienced by IL-2 patients included chills, pruritus, nausea, vomiting, diarrhea, hyperbilirubinemia, renal failure, hypotension, anemia, and thrombocytopenia. Patients receiving IL-4 experienced generalized edema, hypotension, pulmonary edema, oliguria, gastric ulceration, and severe nasal congestion in the absence of rhinorrhea, nasal pruritus, and sneezing. Subjectively, the dose-limiting factor for IL-4 administration was often the discomfort caused by nasal congestion. The effects of cytokine administration on nasal mucosal and basophil reactivity were studied in these patients. The effects of in vivo administration of IL-4 on nasal reactivity are being published elsewhere. However, in that study, elevated levels of histamine were detected in the nasal secretions of patients who had received IL-4. We report here the effects of in vivo administration of IL-2 and/or IL-4 on basophil histamine release induced by anti-IgE, calcium ionophore A23187, and pooled human nasal secretions.

MATERIALS AND METHODS

Subjects. Four different groups of patients, 28 to 68 years of age, were studied. The first three groups consisted of patients participating in various arms of an NIH pilot protocol to treat either metastatic malignant melanoma or renal cell carcinoma: (1) six patients who received IL-4 (10 to 20 μg/kg/three times daily [tid] dose) alone; (2) seven who received the combination of IL-4 (2 to 6 μg/kg/tid dose) and IL-2 (216,000 to 720,000 IU/kg/tid dose); and (3) three who received IL-2 (216,000 to 720,000 IU/kg/tid dose) alone. The principal side effects of IL-2 consisted of malaise, nausea, vomiting, diarrhea, marked fluid retention, oliguria, and pulmonary congestion. Side effects of IL-4 included generalized edema, gastritis with ulceration, hypotension, oliguria, and severe nasal congestion without rhinorrhea, resistant to H-1 antihistamines and decongestants. All of these subjects received the H-2 antihistamine, ranitidine (10 mg intravenously [IV] per hour), to control the ulcerogenic side effects of IL-4 and/or IL-2. In addition, some subjects received one or more of the following...
medications, as indicated: acetaminophen, furosemide, promethazine, triethylperazine, or droperidol. To control for the effects of ranitidine on histamine release, a control group of five patients receiving ranitidine (300 to 4,600 mg/d) for treatment of Zollinger-Ellison syndrome was also studied.

**Basophil histamine release.** Ten to 20 mL of peripheral blood were obtained with consent from each patient before receiving immunomodulator therapy, and at the completion of therapy (2 to 3 days). Blood was obtained from Zollinger-Ellison patients while on long-term ranitidine (300 to 4,600 mg/d) and after discontinuation of ranitidine for at least five half-lives. Basophil histamine release experiments were performed as previously described. Briefly, leukocytes were isolated over Histopaque 1.077 (Sigma, St Louis, MO), washed extensively in HEPES-buffered Hanks' Balanced Salt Solution without calcium and magnesium (HBSS without C&M; Gibco, Grand Island, NY), and resuspended in 0.75 mL HEPES-buffered HBSS with C&M. The washed leukocytes (10 μL) were incubated with 75 μL buffer (HBSS with C&M) or with each of three stimulants (A23187, 0.01 to 0.3 μg/mL [Sigma]; antihuman IgE, 0.03 to 1 μg/mL [Kirkegaard & Perry, Gaithersburg, MD]; or pooled nasal washings [1:27:full strength]) for 60 minutes at 37°C. Reactions were terminated by the addition of ice-cold buffer followed by centrifugation and the supernatants removed. Histamine was assayed both in the supernatants and in cell lysates, unstimulated cells using a commercially available radioimmunoassay (AMAC, Westbrook, ME). Net percent histamine release is defined as histamine in supernatants from stimulated cells minus histamine in supernatants from cells incubated in buffer, divided by total cellular histamine.

**Preparation of human nasal washings.** Nasal washings were obtained and pooled from eight atopics and nonatopic healthy volunteers as previously described. Briefly, an 8 French soft rubber catheter was insertedatraumatically 3 to 4 cm along the floor of each nares and attached to suction. Normal saline (4 mL) was sprayed into each nares and the washed secretions collected into a single batch that was aliquotted, stored at -80°C, and used throughout the study.

**Statistics.** Differences in stimulant-induced histamine release preimmunomodulator treatment versus postimmunomodulator treatment were analyzed by Wilcoxon signed rank when individual data points were being compared, and by three-way analysis of variance (ANOVA) when entire dose-response curves were being compared. When dose-response curves were found to vary significantly, stimulant dose effects and differences between stimulants were analyzed post hoc by Fisher's protected least significant difference (LSD) test.

### RESULTS

**Effects on IgE-mediated histamine release.** To determine whether IL-4 or IL-2 affected IgE-mediated basophil histamine release, basophils were obtained before and after 3 days of IV IL-2 and/or IL-4 treatment, incubated with anti-IgE (0.03 to 1 μg/mL), and histamine release measured. The results are presented in Fig 1. Anti-IgE caused equivalent amounts of dose-related histamine release from all four groups. IL-2 and IL-4 had any effect on basophil responsiveness to anti-IgE. There were also no significant differences found in the IL-2 group, although there was a trend towards enhancement of anti-IgE-induced histamine release at the highest dose of anti-IgE (19 ± 6.7 v 35.7 ± 12.8, preinduction and postinduction, respectively; *P = .1, N = 3). The maximal histamine release induced by anti-IgE (the optimal dose of anti-IgE varied among subjects) decreased after IL-4 (43.6 ± 14 v 26 ± 11 before and after IL-4, respectively), but the differences did not achieve statistical significance for this or any of the other treatment groups (Table 1). However, analysis of the entire dose response curve by three-way ANOVA indicated that IL-4 significantly (*P < .05) reduced anti-IgE-induced histamine release (Fig 1). Thus, IL-4 administered IV for 3 days inhibits ex vivo IgE-mediated basophil histamine release, while there is a trend for enhancement by IL-2.

**Effects on histamine release induced by nasal washings.** One of the dose-limiting side effects of IL-4 is nasal congestion, and nasal washings from patients receiving IL-4 contain increased levels of histamine. The effect of IL-2 and/or IL-4 treatment in vivo on basophil histamine release induced in vitro by unstimulated human nasal washings was therefore examined. Undiluted nasal washings induced low amounts of histamine release from basophils of all four groups before treatment (range, 6.5% to 13.1% net histamine release). Treatment with IL-2, IL-4, and with IL-2 plus IL-4 generally resulted in enhanced basophil histamine release across the dose-response induced by nasal washings (*P = .03, .05, and .02, respectively by ANOVA) (Fig 2). The enhancement by IL-2 was significantly greater than that induced by IL-4 alone and by the combination of IL-2 and IL-4 (*P < .001, by Fisher's protected LSD test). Rani tidine had no effect at any dose of nasal washings on nasal washings-induced histamine release. The magnitude of histamine release induced by full-strength nasal washings was also increased after IL-4 (6.5% ± 6.2% v 15.3% ± 7.6%; *P = .04, by Wilcoxon signed rank), but not IL-2 plus IL-4 treatment. There was a trend for the magnitude of histamine release induced by full-strength nasal washings to increase after IL-2 (14.1 ± 10.1 v 58.3 ± 25.2, preinduction v postinduction, respectively; *P = .1, by Wilcoxon signed rank, N = 3) but the increase was not statistically significant (Table 1). Thus, both IL-4 and IL-2 caused augmenta-

### Table 1. Effect of Therapy on Maximal Basophil Histamine Release Induced by Anti-IgE, Nasal Washings, and Calcium Ionophore A23187

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Anti-IgE (0.03-1 μg/mL)</th>
<th>Nasal Washings (1/27:full)</th>
<th>A23187 (0.01-0.3 μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
</tr>
<tr>
<td>IL-2 (N = 3)</td>
<td>54.8 ± 13.7</td>
<td>14.4 ± 10.1</td>
<td>66.4 ± 23.1</td>
</tr>
<tr>
<td>IL-4 (N = 6)</td>
<td>42.7 ± 11.2</td>
<td>58.3 ± 26.2</td>
<td>44.2 ± 8.7</td>
</tr>
<tr>
<td>IL-2 and IL-4 (N = 7)</td>
<td>43.6 ± 14.1</td>
<td>6.8 ± 6.2*</td>
<td>28.9 ± 10.9</td>
</tr>
<tr>
<td>Post</td>
<td>26.0 ± 11.6</td>
<td>15.3 ± 7.6</td>
<td>25.3 ± 9.1</td>
</tr>
<tr>
<td>Rani tidine</td>
<td>36.6 ± 15.7</td>
<td>7.5 ± 2.8</td>
<td>35.7 ± 10.2</td>
</tr>
<tr>
<td>Pre</td>
<td>29.6 ± 10.6</td>
<td>14.5 ± 5.3</td>
<td>37.0 ± 7.7</td>
</tr>
<tr>
<td>Post</td>
<td>32.8 ± 8.9</td>
<td>13.1 ± 4.4</td>
<td>50.9 ± 11.1</td>
</tr>
<tr>
<td>A23187 (0.01-0.3 μg/mL)</td>
<td>34.7 ± 13.0</td>
<td>18.4 ± 13.0</td>
<td>42.7 ± 11.7</td>
</tr>
</tbody>
</table>

Data represent the mean ± SEM of the maximal response of each subject to the various agonists for each of the four treatment groups. Maximal histamine release was not necessarily achieved with the highest dose of stimulant used.

*P < .05 by Wilcoxon ranked sign test.
EFFECT OF IL-2 AND IL-4 ON BASOPHILS

Fig 1. Effect of IV IL-2, IL-4, IL-2 plus IL-4, and oral ranitidine on net percentage basophil histamine release induced by various concentrations (0.03 to 1 pg/mL) of anti-IgE. Basophils were obtained before (○) and after (□) 3 days of either (A) IL-2 (N = 3), (B) IL-4 (N = 6), or (C) the combination of IL-2 and IL-4 (N = 7). Basophils were obtained from patients receiving ranitidine at steady-state levels (●) and after stopping ranitidine treatment (□) for at least five half-lives (D) (N = 5). All data are presented as mean ± SEM. Pre- and post-IL-4 histamine release curves were significantly different (P = .05, three-way ANOVA).

Fig 2. Effect of IV IL-2, IL-4, IL-2 plus IL-4, and oral ranitidine on net percentage basophil histamine release induced by various concentrations (1/27 to neat) of pooled human nasal washings. Basophils were obtained before (□) and after (●) 3 days of receiving either (A) IL-2 (N = 3), (B) IL-4 (N = 6), or (C) the combination of IL-2 and IL-4 (N = 7). Basophils were obtained from patients receiving ranitidine at steady-state levels (●) and after stopping ranitidine treatment (□) for at least five half-lives (D) (N = 5). All data are presented as mean ± SEM. *P ≤ .05 comparing responses to individual doses of nasal washings pretreatment and posttreatment (Wilcoxon signed rank). The following pretreatment and posttreatment curves were significantly different from each other as compared by three-way ANOVA: IL-2, P = .03; IL-4, P = .05; IL-2 plus IL-4, P = .02.

**Discussion**

This is the first report of the effects of in vivo administration of IL-2 and/or IL-4 on basophil histamine release. IgE-mediated histamine release was inhibited by IL-4; however, this effect was lost when IL-4 was administered in conjunction with IL-2. In contrast, there was a trend towards enhancement by IL-2 of IgE-mediated histamine release, supporting the in vitro observations of Morita et al.20 When IL-2 and IL-4 were administered together, the combined actions resulted in no net change in basophil responsiveness to anti-IgE. These opposing effects of IL-2 and IL-4 are not surprising, and have been observed in other systems. IL-4 has been shown to block the upregulation of IL-2 receptors induced by IL-2 in normal human B cells.25 The effect of IL-4 on basophil IL-2 receptors is not known. The inhibitory effect of IL-4 on IgE-mediated basophil histamine release was unexpected, however, because other basophil growth factors, such as IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), induce and/or enhance IgE-mediated histamine release.12-15

Patients receiving IV IL-4 had elevated levels of histamine in their nasal secretions.24 Pooled crude nasal washings from normal atopic and nonatopic volunteers caused basophil histamine release from all four groups of patients. IV administration of both IL-4 and IL-2 enhanced basophil histamine release induced by subsequent exposure to crude preparations of nasal washings, although the effect of IL-2 was significantly greater than the effect of IL-4. Interestingly, the combination of IL-2 and IL-4 resulted in an effect equivalent to that of IL-4 alone. These data suggest that IL-4 dampened the actions of IL-2, possibly by inhibiting
were obtained before tions (0.01 to basophil histamine release is not known. One possible steady-state levels (0) and after stopping ranitidine treatment at least five half lives (D) (N SEM. No significant differences were observed.

There is evidence to suggest that histamine release inhibi-
tory factor, which specifically inhibits cytokine-, but not IL-8 from stimulated monocytes.26 It is possible that the production of IL-8 by blood mono-
cells origin that induce basophil histamine release.28-29 Thus, it is possible that the production of IL-8 by blood mono-
cytes or neutrophils31 might inhibit basophil histamine release when crude leukocytes are used as the basophil source.

The identity of the histamine-releasing factor in nasal lavage fluids that was modulated by IL-2 and IL-4 could not be examined in these patients. A 25 to 30 Kd histamine releasing factor that does not bind to DE52 and is IgE dependent has been described in human nasal secretions.29 However, we did not wish to limit our examination of nasal secretions to this one factor. Subsequent purification of the factor(s) responsible for inducing histamine release would have been desirable; however, there were limited numbers of patients receiving IL-2 and/or IL-4 who were available for study. The patients studied were subjected to multiple procedures and blood draws for clinical as well as various research purposes. In addition, many patients developed anemia from their immunomodulatory therapy. Thus, it was not ethical to obtain enough blood to provide sufficient basophils to screen column fractions for individual histamine-releasing factors to which the patients under study had become hyperresponsive.

Neither IL-2 nor IL-4 had any effect on basophil histamine release stimulated by the calcium ionophore A23187. This is in contrast to a previous report that IL-2 enhances A23187-induced basophil histamine release.20 That study, however, was performed in vitro using a short preincuba-
tion with IL-2, while in the current study subjects were treated in vivo for 3 days with IL-2 before their basophils were tested.

To control for the effects of ranitidine, which all subjects received, a separate group of patients receiving high-dose ranitidine for treatment of Zollinger Ellison's syndrome were studied on and off of ranitidine. Ranitidine caused no alterations in basophil reactivity to anti-IgE, nasal washings, or A23187, suggesting that the effects seen in the IL-2, IL-4, and IL-2 plus IL-4 groups were due to the cytokines administered. These results are in contrast with previous observations in which ranitidine, in low doses, inhibited IgE-mediated histamine release, while at doses above 10^-4 mol/L ranitidine, augmented histamine release.32 Those results, however, do not necessarily contradict the results presented herein because the referenced study used in vitro administration of ranitidine, while the present study exam-
ined the effects of oral ranitidine. The subjects studied were ill and received a variety of other medications, as indicated and outlined above. Controlling for the effects on basophils of these other drugs was not technically feasible, because these other drugs were not received by all subjects and there was no uniformity in the prescription of these drugs amongst those who received them. However, none of these other drugs are known to have the potential to affect basophil function.
REFERENCES


25. Lee HK, Xia X, Choi YS: IL-4 blocks the up-regulation of IL-2 receptors induced by IL-2 in normal human B cells. J Immunol 144:3431, 1990


Effects of in vivo administration of interleukin-2 (IL-2) and IL-4, alone and in combination, on ex vivo human basophil histamine release

MV White, Y Igarashi, BE Emery, MT Lotze and MA Kaliner

Updated information and services can be found at:
http://www.bloodjournal.org/content/79/6/1491.full.html

Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml